Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on RNA interference (RNAi) technology. The company operates within the biopharmaceutical and oncology drug development industries, with a primary emphasis on modulating gene expression to enhance anti-tumor immune responses. Phio’s core strategy centers on selectively silencing genes that suppress immune cell activity, thereby improving the effectiveness of immune-mediated cancer therapies.
The company’s primary business activity is the research and development of RNAi-based therapeutics, with no commercialized products to date and revenues primarily limited to collaboration-related income and research activities. Phio is uniquely positioned through its proprietary self-delivering RNAi (sd-rxRNA®) platform, which is designed to enable efficient intracellular delivery without the need for lipid nanoparticles or viral vectors. Phio Pharmaceuticals Corp. was originally founded in 2011 and underwent strategic refocusing over time, transitioning from broader RNAi applications to a concentrated focus on immuno-oncology, particularly adoptive cell therapies such as CAR-T and tumor-infiltrating lymphocytes (TILs).
Business Operations
Phio operates as a single-reportable-segment company focused on RNAi-based immuno-oncology therapeutics, with activities spanning early-stage discovery, preclinical research, and clinical development. Its lead programs are designed to be used either ex vivo in engineered immune cells or potentially in vivo, targeting immune checkpoint-related genes such as PD-1 and other intracellular regulators of immune suppression. The company generates no product sales revenue and funds operations primarily through equity financing and, to a lesser extent, research collaborations.
Operationally, Phio conducts its research through a combination of internal capabilities and outsourced contract research organizations, while retaining ownership of its core RNAi technology and intellectual property. The company has engaged in collaborations with academic institutions and biotechnology partners to evaluate its technology in combination with cell-based immunotherapies. Data regarding long-term or large-scale commercial partnerships remains limited based on publicly available disclosures.
Strategic Position & Investments
Phio’s strategic direction is centered on advancing its sd-rxRNA® platform into clinical validation, particularly in combination with existing and emerging cell therapy approaches. Growth initiatives focus on progressing clinical trials, expanding the applicability of its RNAi constructs to additional immune targets, and pursuing partnerships with larger biopharmaceutical companies active in cell therapy and oncology. The company has not reported any material acquisitions in recent years and primarily invests capital into internal R&D programs.
The company’s pipeline includes multiple preclinical and early clinical candidates targeting immune checkpoint pathways, positioning Phio within the emerging intersection of RNA therapeutics and immuno-oncology. While RNA-based drugs are an active and competitive field, Phio’s emphasis on self-delivering constructs represents a differentiating technological approach. Information regarding minority investments or a diversified portfolio of subsidiaries is limited; Phio operates primarily through its parent corporate structure without significant operating subsidiaries.
Geographic Footprint
Phio Pharmaceuticals Corp. is headquartered in the United States, with its principal executive offices located in Massachusetts. The company’s operational footprint is primarily domestic, with research activities conducted in the U.S. and through international contract research organizations as needed for preclinical and clinical development. It does not currently maintain large-scale manufacturing or commercial operations in any region.
Although Phio does not have significant direct international sales or marketing presence, its clinical and research collaborations may involve partners or trial sites outside the United States. The company’s strategic outlook includes potential global applicability of its technology, but its current operational influence remains concentrated in North America.
Leadership & Governance
Phio is led by an executive team with experience in biotechnology, oncology, and RNA-based drug development. The leadership emphasizes scientific rigor, capital efficiency, and strategic partnering as core elements of its governance philosophy, reflecting the company’s clinical-stage profile and reliance on innovation-driven value creation.
Key executives include:
- Robert Bitterman – President and Chief Executive Officer
- Allison Green – Chief Financial Officer
- Mark D. Leuchtenberger – Chief Business Officer
- Gintaras Vaitkevicius – Vice President, Research and Development
The company is governed by a board of directors with backgrounds in life sciences, finance, and corporate governance, providing oversight aligned with regulatory compliance and long-term shareholder interests.